Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?
Lifestream Technologies
A smart card-enabled Cholesterol Monitor will be available to consumers by year-end pending FDA approval, the Post Falls, Idaho-based company says. The device uses one drop of blood to determine cholesterol levels in three minutes; the results are then encrypted and downloaded on the included Privalink Microsoft Smart Card for Windows, allowing them to be sent to doctors or pharmacists via the Internet; the data also can be delivered in person. Other software records cholesterol levels for later review. Print advertising and an infomercial will promote the product to consumers and professionals, who must cooperate in establishing an information system to receive and store the data. The monitor will retail for $129.95, with packets of six test kits selling for $19.95
More from Archive
• By
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
• By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
• By
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
• By
The ups – and some downs – of the US FDA’s prescription, biosimilar, and generic user fees for FY 2026 are tabulated by the Pink Sheet.
• By
In line with new President Lee’s campaign pledges, South Korea's newly confirmed health minister is expected to tackle key issues including a prolonged doctors' conflict, essential drug supplies and R&D support for the industry.
• By
The removal of CBER Director Prasad comes after a wave of right-wing backlash to his appointment over the past few days that was also critical of his decision to ask Sarepta to suspend all sales of the DMD gene therapy Elevidys. FDA reversed its decision the day before Parsad's departure.